Noor Ul Ain Rehman
Tue, March 31, 2026 astatine 10:06 AM CDT 2 min read
The standing update came the aforesaid time Lantheus Holdings, Inc. (NASDAQ:LNTH) announced that the U.S. Food and Drug Administration extended its reappraisal of the New Drug Application for LNTH-2501 (Gallium 68 edotreotide) by 3 months to June 29, 2026, with the hold not related to the efficacy oregon information information of LNTH-2501.
Lantheus Holdings, Inc. (NASDAQ:LNTH) provides diagnostic imaging and atomic medicine products, processing products that enactment healthcare professionals successful diligent absorption and outcomes and assistance clinicians observe cardiovascular disease. The company’s operations are divided into the U.S. and International geographical segments.
While we admit the imaginable of LNTH arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

2 days ago
9






English (CA) ·
English (US) ·
Spanish (MX) ·